EP3302501
COMBINATION OF A PD-1 ANTAGONIST AND CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER
:
EP einkaleyfi: Þýðing ekki lögð inn:
26.5.2016:
22.9.2021:
16804054.1
:
25.5.2036
:
COMBINATION OF A PD-1 ANTAGONIST AND CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER
26.5.2016
22.9.2021
:
Merck Sharp & Dohme Corp.:
126 East Lincoln Avenue, Rahway, NJ 07065-0907, US
:
Surefire Medical, Inc.:
d/b/a TriSalus Life Sciences 6272 West 91st Avenue, Westminster, CO 80031, US
:
YU, Ying:
Palo Alto, California 94304, US
:
DENKER, Andrew Evan:
Ardmore, PA 19003, US
:
SADEKOVA, Svetlana:
Palo Alto, California 94304, US
:
PHAN, Uyen Truong:
Palo Alto, California 94304, US
:
KASTELEIN, Robert A.:
Palo Alto, California 94304, US
:
KAUFMAN, David Ross:
North Wales, Pennsylvania 19454, US
:
COFFMAN, Robert L.:
Berkeley, California 94710-2753, US
:
GUIDUCCI, Cristiana:
Berkeley, California 94710-2753, US
:
JANSSEN, Robert S.:
Berkeley, California 94710-2753, US
:
201562168449 P:
29.5.2015:
US
:
201562169309 P:
1.6.2015:
US
:
US2016034275:
26.5.2016
:
A61K 31/7115, A61K 39/39, A61K 45/06, A61K 9/00, A61N 5/00, C07K 14/435, A61P 35/00